Biostem Technologies Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OID
Andrew Van Vurst reports beneficial ownership of 3,854,452 shares, representing 18.4% of BioStem Technologies, Inc. common stock, primarily through vested options and direct holdings.
OID
Jason Matuszewski has reported beneficial ownership of 3,665,899 shares, representing 17.4% of BioStem Technologies' common stock, as of September 30, 2026.
OID
The PNC Financial Services Group, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.40% of Biostem Technologies, Inc. common stock.